Abstract Number: 535 • 2018 ACR/ARHP Annual Meeting
Is There Achilles Tendon Damage in Rheumatoid Arthritis Patients?
Background/Purpose: Ankle involvement is common in Rheumatoid Arthritis (RA). It has been reported that more than 90 % of patients develop ankle symptoms over the…Abstract Number: 536 • 2018 ACR/ARHP Annual Meeting
Prevalence and Relative Factors for Frailty in Patients with RA from a Prospective Observational Study
Prevalence and relative factors for frailty in patients with RA from a prospective observational study Background/Purpose: Frailty is defined as degradation of physical and cognition…Abstract Number: 537 • 2018 ACR/ARHP Annual Meeting
Increased Risk of Incident Chronic Kidney Disease Among Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Cohort Studies
Increased Risk of Incident Chronic Kidney Disease among Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis of Cohort Studies AbstractBackground/Purpose: Patients with rheumatoid arthritis (RA)…Abstract Number: 538 • 2018 ACR/ARHP Annual Meeting
Type 1 Diabetes in RA: Comparison with Type 2 and Its Association with RA Severity and Treatment
Background/Purpose: DMARD treatment for Rheumatoid Arthritis (RA) has been shown to improve the glucose control and reduce the incidence of diabetes, usually assumed to be…Abstract Number: 539 • 2018 ACR/ARHP Annual Meeting
Thyroid Function in Early Versus Established Rheumatoid Arthritis
Background/Purpose: Thyroid dysfunction is common in rheumatoid arthritis (RA). Subclinical hypothyroidism is the first most common, followed by clinical hypothyroidism. Thyroid dysfunction in RA had…Abstract Number: 540 • 2018 ACR/ARHP Annual Meeting
Echocardiographic Abnormalities in Rheumatoid Arthritis Patients Compared to Age, Sex and Traditional Cardiovascular Risk Factors Matched Controls
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease of the joints with several extra-articular features. Cardiovascular disease (CVD) mortality accounts for 40-50% of…Abstract Number: 541 • 2018 ACR/ARHP Annual Meeting
Prevalence of Sjögren’s Syndrome in Patients with RA Enrolled in a Large Observational US Registry
Background/Purpose: Sjögren’s syndrome is a known co-existing autoimmune disease in patients with RA, but its prevalence and impact on RA are poorly understood. The aims…Abstract Number: 542 • 2018 ACR/ARHP Annual Meeting
Incidence and Prevalence of Interstitial Lung Disease in the US Population and in Patients with RA By Anti-Citrullinated Protein Antibody Status
Background/Purpose: Interstitial lung disease (ILD) is recognized as the most common pulmonary extra-articular manifestation of RA. The hazard ratio for 30-year risk of ILD in…Abstract Number: 543 • 2018 ACR/ARHP Annual Meeting
Disease Severity Among Bio-Naive RA Patients on Csdmards
Background/Purpose: Conventional synthetic disease-modifying anti-rheumatic drugs (csDMARD) are recommended as the first-line treatment for patients with rheumatoid arthritis (RA). Guidelines recommend escalation of treatment to…Abstract Number: 544 • 2018 ACR/ARHP Annual Meeting
Does Anti-Citrullinated Protein Antibody Status Modify Treatment Effect of Certain Biologic DMARDs?
Background/Purpose: Multiple therapeutic options with different mechanistic actions are available to treat patients (pts) with RA. However, selecting therapies by the characteristics of pts with…Abstract Number: 545 • 2018 ACR/ARHP Annual Meeting
How to Treat Rheumatoid Arthritis Patients When Methotrexate Has Failed? Results from the Meteor Registry
Background/Purpose: After failure of initial methotrexate (MTX) treatment in rheumatoid arthritis (RA) patients, various treatment options can be considered. To date, evidence about the preferred…Abstract Number: 546 • 2018 ACR/ARHP Annual Meeting
Baricitinib: Early Vs. Delayed Start in Patients with Rheumatoid Arthritis
Background/Purpose: Baricitinib (bari) is an oral JAK1/JAK2 inhibitor approved for the treatment of moderately to severely active RA in adults in over 40 countries including…Abstract Number: 547 • 2018 ACR/ARHP Annual Meeting
Corticosteroid Bridging Strategies with Methotrexate Monotherapy in Early Rheumatoid and Undifferentiated Arthritis; A Comparison of Efficacy and Toxicity in 2 Clinical Trials
Background/Purpose: What is the optimal glucocorticoid (GC) bridging therapy with MTX monotherapy in early arthritis? Methods: In trial A, early RA and UA (arthritis in ≥1…Abstract Number: 548 • 2018 ACR/ARHP Annual Meeting
Persistence in Low Disease Activity or Remission with Etanercept Monotherapy in Patients with Rheumatoid Arthritis: Results from the Corrona Registry
Background/Purpose: Monotherapy with etanercept (ETN) may be a viable therapeutic option for maintenance of patients with rheumatoid arthritis (RA) who prefer to eliminate potential burdens…Abstract Number: 549 • 2018 ACR/ARHP Annual Meeting
Unmet Treat-to-Target Goals with Available Targeted Immunomodulators in the Management of Rheumatoid Arthritis: Real World Evidence from the Corrona Registry
Background/Purpose: Targeted immunomodulators (TIMs) have revolutionized the therapy of RA and made low disease activity (LDA) a realistic goal for patients. Given the multiple therapy…
ACR Meeting Abstracts